Exhibit 99.1 Assertio Reports Third Quarter 2024 Financial Results Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, IL. – November 11, 2024 – Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, ...

Financial Data and Key Metrics Changes - Total product sales for Q3 2024 were $28.7 million, down from $30.7 million in Q2 2024, primarily due to a decline in INDOCIN sales [32] - ROLVEDON sales were $15 million in Q3 2024, compared to $15.1 million in Q2 2024, driven by continued volume growth offset by lower net pricing [32] - INDOCIN sales decreased to $5.7 million in Q3 2024 from $6.9 million in Q2 2024, attributed to lower net pricing due to generic competition [33] - Reported gross margin improved to 74% in Q3 2024 from 71% in Q2 2024, primarily due to inventory step-up amortization and write-downs not repeating [33] - GAAP net income for Q3 2024 was a loss of $2.9 million, an improvement from a loss of $3.7 million in Q2 2024 [35] - Adjusted EBITDA for Q3 2024 was $5.3 million, up from $5 million in Q2 2024, due to lower operating expenses [35] Business Line Data and Key Metrics Changes - ROLVEDON maintained a stable market share of approximately 33% in the oncology community clinic space, despite a dip in demand due to seasonality [22] - INDOCIN's market share is holding steady at around 50% of the ex-compounding market, with efforts to maintain and optimize pricing [25] - Sympazan has seen record demand levels in prescriptions due to new sales and marketing tactics, indicating potential for growth [26] Market Data and Key Metrics Changes - The GCSF market is highly competitive, with pricing declines anticipated to continue as market share equalizes [41] - ROLVEDON is positioned as a safe and effective non-biosimilar GCSF, which is resonating well with providers and patients [23] Company Strategy and Development Direction - The company is focused on stabilizing operations while transitioning from INDOCIN to ROLVEDON, aiming for transformational growth [18] - Plans to expand ROLVEDON's market presence into hospitals and community oncology clinics are underway, with a long-term growth strategy in mind [47] - The company is exploring both smaller and larger acquisition opportunities to enhance its portfolio, with a focus on strategic fit and pricing [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ROLVEDON's safety and efficacy, emphasizing its role in future growth [10] - The company is committed to maintaining a strong balance sheet and executing a focused go-to-market strategy [20] - Management acknowledged the challenges posed by generic competition and dynamic pricing in the GCSF market but remains optimistic about future growth [41][47] Other Important Information - The company announced changes in its Board of Directors, including the retirement of Peter Staple and the appointment of Heather Mason as Chairwoman [14][16] - The same-day dosing trial for ROLVEDON concluded, with data to be presented at an upcoming symposium, which could influence future market positioning [24] Q&A Session Summary Question: Guidance for the remainder of the year - The company is maintaining its guidance range due to ongoing fluctuations in key areas, focusing on stabilizing the business and monitoring the competitive landscape [38] Question: Update on potential acquisitions - The company is considering both smaller and larger deals, with a preference for a more robust acquisition if the right opportunity arises [39] Question: Pricing stabilization for ROLVEDON - The GCSF market remains competitive, and pricing declines are expected to continue as market share stabilizes [41] Question: Timeline for NCCN guidelines on same-day dosing - The data will be made public in December, with a potential six-month timeline for consideration by NCCN [42] Question: Future growth expectations for ROLVEDON - The company anticipates continued growth for ROLVEDON as it expands into new markets, viewing it as a long-term asset [47] Question: SG&A expense outlook - SG&A expenses are expected to remain at current levels, reflecting seasonal trends and restructuring efforts [48] Question: Board member retirements - Peter Staple's retirement was planned due to approaching term limits, while Dr. Vacirca stepped back to focus on other business interests [50][51] Question: Market dynamics driving new customers to ROLVEDON - ROLVEDON's appeal lies in its safety and effectiveness, along with strategic contracting that helps maintain market share [53] Question: Future gross margin trends - The company aims to maintain gross margins between 70% and 75% in 2024, despite anticipated erosion due to product mix changes [58]

Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this drugmaker would post a loss of $0.02 per share when it actually produced a loss of $0.04, delivering a surprise of -100%. Over the last four quarters, the company has surpassed co ...

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024. "Third quarter results reflected solid perform ...

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chi ...

LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Brendan O'Grady, Chief Executive Officer, will participate in a fireside chat discussion as part of the Maxim Group 2024 Healthcare Virtual Summit. The fireside chat with Mr. O'Grady, hosted by Maxim Group research analyst Naz Rahman, will occur Tuesday, Octob ...

Assertio Holdings (ASRT) was materially affected by its flagship drug going generic, but the pharma firm still stands to make a major comeback. duckycards/E+ via Getty Images Assertio Holdings, Inc. (NASDAQ:ASRT) shares took a heavy beating in 2023 when the pharma firm's flagship drug went generic. Thus far in 2024, ASRT stock has stabilized, but price action remains choppy. At first glance, this suggests waning confidence in the "comeback story" surrounding the company. Taking a closer look, there's more t ...

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor meetings at two investor conferences taking place in New York City during September 10-12, 2024. Assertio will participate in the HC Wainwright Conference, which will take place September 10-11, 2024 at ...

Financial Data and Key Metrics - Total product sales for Q2 2024 were $30.7 million, down slightly from $31.9 million in Q1 2024 [14] - Rolvedon sales increased to $15.1 million in Q2 2024, up from $14.5 million in Q1 2024, driven by continued volume growth [15] - Indocin sales declined to $6.9 million in Q2 2024 from $8.7 million in Q1 2024 due to generic competition [16] - Gross margin for Q2 2024 was 71%, up from 65% in Q1 2024, with inventory write-downs impacting margins by 3 percentage points [16] - Adjusted EBITDA for Q2 2024 was $5 million, down from $7.4 million in Q1 2024, primarily due to lower product sales and increased inventory write-downs [18] - Cash and short-term investments at the end of Q2 2024 were $88.4 million, up from $80.7 million in Q1 2024 [19] Business Line Performance - Rolvedon continues to show strong demand growth, with Q2 2024 marking the 6th consecutive quarter of volume growth [10] - Indocin market share is holding at internal target levels despite generic competition, with one generic competitor currently in the market [11] - Sympazan and Otrexup collectively contributed $4.7 million in sales, with Sympazan showing modest growth while Otrexup remained stable [43] Market and Competitive Dynamics - Rolvedon is positioned as a non-biosimilar product, offering stability and predictability to providers and patients, which is resonating well in the market [10] - The company expects potential additional generic competitors for Indocin by the end of 2024, though the timing remains uncertain [29] - Rolvedon's same-day dosing trial completed enrollment in Q2 2024, with initial data expected to be presented at a major medical conference later this year [10] Strategic Direction and Industry Competition - The company is focused on steady execution, driving cash flow, and identifying accretive assets to scale its platform [9] - Rolvedon is expected to remain a key growth driver for the company in the coming years, with continued growth anticipated in 2025 [38] - The company is actively evaluating potential acquisitions that fit its commercial model, with a focus on assets that offer patent protection or exclusivity [30] Management Commentary on Operating Environment and Future Outlook - Management remains optimistic about Rolvedon's growth trajectory and its ability to deliver value in the oncology market [38] - The company is managing the impact of generic competition on Indocin and is focused on maintaining competitive pricing and market share [11] - Management is confident in the company's ability to generate cash flow and leverage its balance sheet for future growth opportunities [12] Other Important Information - The company completed enrollment for Rolvedon's same-day dosing trial in Q2 2024, with initial data expected later this year [10] - Inventory write-downs for late-stage products increased by approximately $1 million in Q2 2024 compared to Q1 2024 [49] Q&A Session Summary Question: What excited Brendan O'Grady about joining Assertio, and what has he learned so far? - Brendan O'Grady joined Assertio due to its solid balance sheet, growth potential, and alignment with his skillset, and his initial impressions have been confirmed after 71 days in the role [22][23] Question: Will the company modify its full-year guidance? - Management will reassess guidance in November after completing nine months of the year [25] Question: How many generic competitors for Indocin are expected by the end of 2024? - The company initially expected 2-3 generics by year-end but may see only one, providing a potential tailwind for Indocin [29] Question: What is the strategy for acquiring new products? - The company is looking for assets that fit its commercial model, with a focus on cash accretion, patent protection, and exclusivity [30] Question: What are the gating factors for closing acquisitions? - Valuations are a key consideration, and the company is in active discussions with several organizations [33] Question: Will Rolvedon continue to grow in 2025? - Rolvedon is expected to remain a growth asset in 2025, with continued volume growth and strategic pricing management [38] Question: How did Sympazan and Otrexup perform in Q2 2024? - Sympazan showed modest growth, while Otrexup remained stable, with both contributing $4.7 million in sales [43] Question: What is the status of Rolvedon's same-day dosing trial? - Enrollment is complete, and initial data will be presented at a major medical conference later this year [45] Question: Would the company consider a larger trial for Rolvedon's same-day dosing if the data is compelling? - Management will evaluate the need for a larger trial based on the trial results and potential value [47]

Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this drugmaker would post a loss of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of 500%.Over the last four quarters, the company has surpassed ...